<DOC>
	<DOC>NCT02095171</DOC>
	<brief_summary>This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 40 healthy subjects.</brief_summary>
	<brief_title>Single Ascending Dose Study of PRX002 in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Healthy subjects Body mass index (BMI) between 1832 kg/m2 with a minimum weight of 46 kg Female subjects must be surgically sterile or postmenopausal or if of childbearing potential must use contraception Male subjects and their partners of childbearing potential must use contraception Positive test for drug of abuse Past or current history of alcohol abuse Positive for hepatitis B, hepatitis C or HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>